Exelixis, an oncology company based in Alameda, California, focuses on developing treatments for difficult-to-treat cancers, with four marketed products including cabozantinib for various cancers. Founded in 2000, it employs 1,310 people.
Exelixis (EXEL) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Exelixis's actual EPS was $0.65, beating the estimate of $0.57 per share, resulting in a 14.00% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
